On October 21, 2025, Solventum announced that Heather Knight has been appointed to serve in the newly created role of Chief Commercial Officer, effective as of November 10, 2025.

1. 01

   On October 21, 2025, Solventum announced that Heather Knight has been appointed to serve in the newly created role of Chief Commercial Officer, effective as of November 10, 2025.

2. 02

   The company said Ms. Knight will oversee all global commercial and R&D operations across the MedSurg, Dental Solutions and Health Information Systems segments and will report directly to CEO Bryan Hanson.

3. 03

   Solventum said Chris Barry, Executive Vice President and Group President of MedSurg, will depart the company effective December 31, 2025. Upon execution and non-revocation of a general release of claims, Mr. Barry is entitled to receive severance benefits under the Solventum Executive Severance Plan, and his outstanding equity awards will be treated in accordance with the applicable award agreements.

4. 04

   The company said Ms. Knight brings over 30 years of leadership experience in the MedTech industry. Most recently, she served as Chief Operating Officer at Baxter International, where she led global sales across 3 business segments, as well as R&D, supply chain and medical and regulatory affairs. She currently serves on the Board of Directors of Waters Corporation.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.